Case Report: Bacteriophage-antibiotic therapy for extensively drug-resistant Acinetobacter baumannii in critically ill patient with respiratory infection
Abstract
Extensively drug-resistant Acinetobacter baumannii (XDR A. baumannii) poses a crucial challenge due to high mortality and limited therapies. Here, we report the successful application of phage-antibiotic synergy in a critically ill patient with two months of ineffective antibiotic treatment. The patient was diagnosed with severe pneumonia due to recurrent infection of XDR A. baumannii, causing severe pulmonary dysfunction. A nebulized phage inhalation combined with intravenous administration of polymyxin B, amikacin, and fosfomycin successfully brought about measurable clinical improvements in 8 days. The clearance of XDR A. baumannii in sputum cultures, coupled with decreased partial pressure of carbon dioxide, substantial absorption of bilateral pulmonary lesions, reduced density of residual infiltrates, and decreased pleural effusion in the patient, collectively confirmed therapeutic efficacy. Our case indicate that bacteriophage-antibiotic therapy is promising to prevent the emergence of resistant mutants and enhance antibacterial efficacy in patient with similar infections.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.